IP Library Granted Patent US 6,852,531
Granted Patent B2
US 6,852,531 · App. 09/955,462 · Granted Feb 8, 2005

Compositions and methods for reproducing and modulating mammalian messenger RNA decapping

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,852,531
App. No.
09/955,462
Granted
Feb 8, 2005
Kind
B2
Abstract

An in-vitro system in which mammalian messenger RNA decapping occurs is provided, for use in identifying modulators, deficiencies, and other aspects of the regulation of RNA turnover.

Claims (42)

1. A mammalian in vitro mRNA decapping system comprising:

a) polysome-free HeLa cell cytoplasmic extract;

b) a methylated cap analog and

c) a cap-labeled mRNA substrate.

2. The mammalian in vitro mRNA decapping system of claim 1 wherein said methylated cap analog is 7me GpppG or 7me GTP.

3. The mammalian in vitro mRNA decapping system of claim 1 wherein said cap-labeled mRNA substrate is labeled at the alpha phosphate of the cap.

4. The mammalian in vitro mRNA decapping system of claim 1 wherein said cap-labeled mRNA substrate is labeled at the cap of said cap-labled mRNA substrate by a label selected from the group consisting of a radioactive label, a non-radioactive isotopic label, a fluorescent moiety, a visibly-detectable moiety, releasable substrate, a co-factor for a chemical reaction, and a co-factor for a enzymatic reaction.

5. The mammalian in vitro mRNA decapping system of claim 1 further comprising means for sequestering proteins that bind to poly(A).

6. The mammalian in vitro mRNA decapping system of claim 1 wherein said HeLa cell cytoplasmic extract is a HeLa S100 cell cytoplasmic extract.

7. The mammalian in vitro mRNA decapping system of claim 6 wherein said HeLa cell cytoplasmic extract is prepared by dialysis of said extract containing 10% glycerol.

8. The mammalian in vitro mRNA decapping system of claim 6 wherein said S100 cell cytoplasmic extract comprises a 100,000×g, 1 hour supernatant from a HeLa cell lysate.

9. The mammalian in vitro mRNA decapping system of claim 1 wherein said cap-labeled mRNA substrate comprises poly(A) or at lea one RNA element.

10. The manunalian in vitro mRNA decapping system of claim 9 wherein said RNA element is a pyrimidine-rich element.

11. The mammalian in vitro mRNA decapping system of claim 9 further comprising means for stimulating decapping of the cap-labeled mRNA substrate wherein the cap-labeled mRNA substrate comprises poly(A).

12. The mammalian in vitro mRNA decapping syst of claim 9 further comprising a cold poly(A) competitor RNA.

13. The mammalian in vitro mRNA decapping system of claim 9 wherein said RNA element is an AU-rich element.

14. The mammalian in vitro mRNA decapping system of claim 13 further comprising means for reducing decapping of the cap-labeled mRNA substrate.

15. The mammalian in vitro mRNA decapping system of claim 13 further comprising an AU-rich element competitor RNA.

16. A kit for measuring mRNA decapping in vitro comprising:

a) a polysome-free HeLa cell cytoplasmic extract;

b) a methylated cap analog; and

c) cap-labeled mRNA substrate.

17. The kit of claim 16 wherein said cap-labeled mRNA substrate is labeled at the alpha phosphate of the cap.

18. The kit of claim 16 wherein said cap-labeled mRNA substrate is labeled at the cap of said cap-labeled mRNA substrate by a label selected from the group consisting of a radioactive label, a non-radioactive isotopic label, a fluorescent moiety, a visibly-detectable moiety, a releasable substrate, a co-factor for a chemical reaction, and a co-factor for an enzymatic reaction.

19. The kit of claim 16 wherein the polysome-free HeLa cell cytoplasmic extract is HeLa S100 cell cytoplasmic extract.

20. The kit of claim 16 wherein the cap-labeled mRNA substrate comprises poly(A).

21. The kit of claim 20 further comprising means for stimulating decapping the cap labeled mRNA substrate.

22. The kit of claim 20 further comprising a cold poly(A) competitor RNA.

23. The kit of claim 16 wherein the cap-labeled nRNA substrate comprises an RNA element.

24. The kit of claim 23 wherein the RNA element is an AU-rich element.

25. The kit of claim 24 further comprising means for reducing decapping the cap-labeled mRNA substrate.

26. The kit of claim 24 further comprising an AU-rich element competitor RNA.

27. A mammalian in vitro mRNA decapping system comprising:

a) a polysome-free HeLa cell cytoplasmic extract;

b) a cap-labeled mRNA substrate; and

c) means for decapping the cap-labeled mRNA substrate.

28. The kit of claim 27 wherein the polysome-free HeLa cell cytoplasmic extract is a HeLa S100 cell cytoplasmic extract.

29. A kit for measuring mRNA decapping in vitro comprising:

a) a polysome-free HeLa cell cytoplasmic extract;

b) a cap-labeled mRNA substrate; and

c) means for decapping the cap-labeled mRNA substrate.

30. The kit of claim 29 wherein the polysome-free HeLa cell cytoplasmic extract is a HeLa S100 cytoplasmic extract.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2013
From: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
To: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Reel/Frame 031700/0446 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2002
From: WILUSZ, JEFFREY; WILUSZ, CAROL; GAO, MIN
To: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
Reel/Frame 012565/0259 →